Much progress has been made in the biological characterization of acute lymphoblastic leukemia (ALL). Many biologic features with prognostic significance have been used together with clinical factors to define patient groups for risk-adapted therapy. [1] [2] [3] However, it is well recognized that the prognostic significance of virtually all variables depends on the type and intensity of treatment. The differences in risk classification, eligibility (eg upper or lower age limit) and composition of ethnic or racial population have made it difficult to compare results between study groups. The comparison is further complicated by the inclusion of only subsets of patients in some publications.
In October 1985, an international workshop (organized by R Mastrangelo) was held in Rome during which recommendations were made to report study results by common, easily available criteria (age and presenting leukocyte count); to collect prospectively information on organ involvement, immunphenotype, genetics and treatment response; and to use standard statistical methods to analyze data. 4 Despite this effort, different risk classifications continue to be used, and a large number of clinical trials had been conducted on subgroups of ALL, especially in the USA. In 1993, the US National Cancer Institute organized a workshop for the US cooperative study groups and major institutions to develop uniform risk criteria. The recommendations published in 1996 5 were more widely accepted. The major groups defined by age and leukocyte count were identical to that of the Rome workshop (Table 1) . While the importance of cytogenetics and molecular genetics were recognized, they were not included in the risk criteria because the tests were not widely available at that time. The criteria also did not include early treatment response. Finally, the classification criteria were not optimal for T cell ALL. 6 In 1995, during the 27th Annual Meeting of the International Society of Pediatric Oncology (SIOP) in Montevideo, H Riehm and M Schrappe organized a workshop in which representatives of major study groups were asked to define essential elements for diagnosis and treatment, and also to provide strategies to avoid or reduce acute and late toxicities of the treatment. The more important outcome of the workshop was an agreement to share data in the investigation of (rare) high-risk subgroups in order to promote more in-depth research on the biology of the disease and development of new therapeutic approaches. This 'Montevideo initiative' was subsequently joined by a large number of study groups. The first project resulted in a consensus on the optimal treatment of children with Philadelphia chromosome-positive ALL, based on the analysis of more than 300 cases treated by 10 study groups or large institutions. 7 The good spirit of cooperation led to two subsequent workshops, one held in Memphis in 1997 (organized by C-H Pui and WE Evans) and the other in Ponte di Legno in April 1999 (organized by G Masera and A Biondi). The workshop in Memphis provided updated results from most of the major cooperative groups. 8 During the conference in Ponte di Legno, there was a discussion of how to compare treatment results across different study groups in order to identify treatment components or regimens that are particularly effective for specific subgroups of patients. A literature search had shown that the UKALL Medical Research Council, the St Jude Children's Research Hospital, the Dana-Farber Cancer Institute ALL Consortium, the Nordic Study Group, the AIEOP group in Italy, and the ALL-BFM Study Group routinely published results on overall patient population, whereas the major US study groups focused on patient subsets partly due to the large patient enrollment. During the conference, it was agreed that all study groups would report overall results for consecutive patients treated in the 1980s and 1990s using the Rome/NCI criteria for B-and T-lineage ALL. As shown in Table 1 , the proportions of standard-and high-risk cases are quite different between B-and T-lineage ALL. In addition, a set of widely available variables was defined for analysis of long-term results of subsets of patients. The results of this unique initiative are presented in this issue of Leukemia. The format will allow the direct comparison of treatment results in overall cohorts and in well-defined subgroups of patients. In addition, updated results of specific study questions are presented.
Despite uniform criteria for data presentation, there are significant differences between studies that probably influence overall treatment results. First, the composition of the study populations differs, mainly with respect to age and ethnic background ( Table 2 ). The US clinical trials include older patients up to 21 years of age, while some European study groups treat patients up to only 15 years of age. African-American and Hispanic patients each represent approximately 10% of the cohort in the US trials. Older patients and the above racial/ethnic groups have had worse outcomes in most trials. Secondly, some studies did not include all patients enrolled during the study period. In some countries, referral of patients is population-based whereas in others, such as the USA, referral depends on local or regional factors. Therefore, some institutions (such as St Jude Children's Research Hospital) have a greater proportion of higher-risk cases. Finally, there are also differences in diagnostic standards (eg cytogenetics were not available from all patients in many studies), and there might be differences in resources available for patient care between various countries. Collectively, nearly 36 000 patients treated with contemporary regimens are included in this series. The data suggest that some subgroups of patients fared particularly well in certain clinical trials. However, because of differences between trials noted above, the reader is cautioned against making direct comparisons between different studies. The data will nevertheless provide clues for the development of new clinical trials.
We would like to apologize to many of our colleagues who have conducted equally important studies but were not invited to participate in this effort. Participation had to be limited to a manageable size. We trust that similar efforts by others on this and other types of hematopoietic malignancies would be well received by the journal.
